James Cassidy

Summary

Affiliation: University of Glasgow
Country: UK

Publications

  1. doi request reprint Radio-chemotherapy in rectal cancer
    Jim Cassidy
    Eur J Cancer 44:1620-1. 2008
  2. ncbi request reprint New oxaliplatin-based combinations in the treatment of colorectal cancer
    J Cassidy
    Cancer Research UK, Department of Oncology, University of Glasgow, Glasgow, UK
    Colorectal Dis 5:1-9. 2003
  3. doi request reprint Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
    J Cassidy
    Glasgow University, UK
    Ann Oncol 22:2604-9. 2011
  4. pmc The third symptom management research trial in oncology (SMaRT oncology-3): a randomised trial to determine the efficacy of adding a complex intervention for major depressive disorder (depression care for people with lung cancer) to usual care, compared t
    Jane Walker
    Cancer Research UK, The University of Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road, Edinburgh, UK
    Trials 10:92. 2009
  5. pmc The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients
    Jane Walker
    University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, Scotland, UK
    Trials 10:18. 2009
  6. doi request reprint Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    Jim Cassidy
    Glasgow University, Garscube Estate, Switchback Rd, Glasgow, Scotland
    J Clin Oncol 26:2006-12. 2008
  7. ncbi request reprint XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
    Jim Cassidy
    CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, United Kingdom
    J Clin Oncol 22:2084-91. 2004
  8. pmc Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
    James Cassidy
    Cancer Research UK, Glasgow, UK
    J Cancer Res Clin Oncol 136:737-43. 2010
  9. ncbi request reprint Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer
    Jim Cassidy
    Beatson Oncology Centre, Glasgow, United Kingdom
    Clin Colorectal Cancer 5:S47-50. 2005
  10. pmc XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    J Cassidy
    Institute of Cancer Sciences, Beatson Oncology Centre, 1053 Great Western Road, Glasgow G12 0YN, UK
    Br J Cancer 105:58-64. 2011

Detail Information

Publications50

  1. doi request reprint Radio-chemotherapy in rectal cancer
    Jim Cassidy
    Eur J Cancer 44:1620-1. 2008
  2. ncbi request reprint New oxaliplatin-based combinations in the treatment of colorectal cancer
    J Cassidy
    Cancer Research UK, Department of Oncology, University of Glasgow, Glasgow, UK
    Colorectal Dis 5:1-9. 2003
    ..However, by building upon the encouraging results achieved using oxaliplatin plus 5FU/leucovorin, the introduction of new agents will eventually translate into significantly improved clinical outcomes...
  3. doi request reprint Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
    J Cassidy
    Glasgow University, UK
    Ann Oncol 22:2604-9. 2011
    ..To compare the effects of oral capecitabine-containing chemotherapy regimens with i.v. 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in patients with gastrointestinal cancers...
  4. pmc The third symptom management research trial in oncology (SMaRT oncology-3): a randomised trial to determine the efficacy of adding a complex intervention for major depressive disorder (depression care for people with lung cancer) to usual care, compared t
    Jane Walker
    Cancer Research UK, The University of Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road, Edinburgh, UK
    Trials 10:92. 2009
    ..Secondary outcomes include severity of anxiety, pain and fatigue; self-rated improvement of depression; quality of life and satisfaction with depression care. TRIAL REGISTRATION: Current controlled trials ISRCTN75905964...
  5. pmc The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients
    Jane Walker
    University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, Scotland, UK
    Trials 10:18. 2009
    ..2) Depression Care for People with Cancer as a supplement to usual care will cost more than usual care alone but will be more cost effective in achieving improvements in patients' depression and quality of life...
  6. doi request reprint Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    Jim Cassidy
    Glasgow University, Garscube Estate, Switchback Rd, Glasgow, Scotland
    J Clin Oncol 26:2006-12. 2008
    ..To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC)...
  7. ncbi request reprint XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
    Jim Cassidy
    CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, United Kingdom
    J Clin Oncol 22:2084-91. 2004
    ..The present studies further characterize efficacy and safety of the XELOX regimen...
  8. pmc Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
    James Cassidy
    Cancer Research UK, Glasgow, UK
    J Cancer Res Clin Oncol 136:737-43. 2010
    ..Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy for patients with metastatic colorectal cancer (mCRC). The relative benefit of bevacizumab in older patients has not been widely studied and is of interest...
  9. ncbi request reprint Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer
    Jim Cassidy
    Beatson Oncology Centre, Glasgow, United Kingdom
    Clin Colorectal Cancer 5:S47-50. 2005
    ..Oral chemotherapy requires just as much care as intravenous chemotherapy and probably requires more attention to patient education and involvement in care decisions...
  10. pmc XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    J Cassidy
    Institute of Cancer Sciences, Beatson Oncology Centre, 1053 Great Western Road, Glasgow G12 0YN, UK
    Br J Cancer 105:58-64. 2011
    ..We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer...
  11. ncbi request reprint First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
    J Cassidy
    Department of Medicine and Therapeutics, University of Aberdeen, UK
    Ann Oncol 13:566-75. 2002
    ..In these trials, capecitabine achieved significantly superior response rates, equivalent time to disease progression and equivalent survival compared with 5-fluorouracil (5-FU)/leucovorin...
  12. pmc Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
    J Cassidy
    Cancer Research UK, Department of Medical Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, UK, and Centre René Gauducheau, Site Hospitalier Nord, Nantes, France
    Br J Cancer 94:1122-9. 2006
    ..This pharmacoeconomic analysis strongly supports replacing 5-FU/LV with capecitabine in the adjuvant treatment of colon cancer in the UK...
  13. ncbi request reprint Tumour-targeted drug and gene delivery: principles and concepts
    Jim Cassidy
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Glasgow, G61 1BD, UK
    Expert Rev Mol Med 6:1-17. 2004
    ..In this review, a brief overview is given of the underlying concepts and principles that help guide the development of such tumour-targeting strategies...
  14. doi request reprint Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    J Clin Oncol 28:4697-705. 2010
    ....
  15. ncbi request reprint Optimizing oxaliplatin-based therapy in metastatic colorectal cancer
    James Cassidy
    Centre for Oncology and Applied Pharmacology, Beatson Institute for Cancer Research, University of Glasgow, Glasgow, Scotland
    Clin Adv Hematol Oncol 6:360-1. 2008
  16. ncbi request reprint Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines
    Weiguang Wang
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom
    Int J Cancer 104:504-11. 2003
    ..As DS has extensive preclinical and clinical experience, translating its anticancer usage from in vitro study to clinical trials is relatively straightforward...
  17. ncbi request reprint The candidate oncogene ZNF217 is frequently amplified in colon cancer
    Patrick H Rooney
    Department of Pathology, University of Aberdeen, UK
    J Pathol 204:282-8. 2004
    ..There was a trend toward poorer survival in patients whose cancers had either gain or loss of ZNF217...
  18. ncbi request reprint Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells
    Weiguang Wang
    Department of Medical Oncology, Beatson Institute for Cancer Research, Glasgow, United Kingdom
    Cancer Res 64:8167-76. 2004
    ..This phenotype may protect resistant cells from cell death induced by incorporation of 5-FU into DNA chains, by allowing time to repair 5-FU-induced damage. Our findings may provide novel targets for tackling 5-FU resistance...
  19. doi request reprint Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer
    Colin A Espie
    University of Glasgow Sleep Centre, Southern General Hospital, Glasgow, G51 4TF United Kingdom
    J Clin Oncol 26:4651-8. 2008
    ..The aim of this study was to investigate the clinical effectiveness of protocol-driven cognitive behavior therapy (CBT) for insomnia, delivered by oncology nurses...
  20. doi request reprint Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial
    Hilary Glen
    Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, Scotland
    Expert Rev Anticancer Ther 8:547-51. 2008
    ..On the basis of the X-ACT trial, capecitabine was approved by the US FDA, the National Institute for Clinical Excellence and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer...
  21. ncbi request reprint Capecitabine in the treatment of colorectal cancer
    Claire Kelly
    Beaston Oncology Centre, Department of Medical Oncology, Glasgow, UK
    Expert Rev Anticancer Ther 7:803-10. 2007
    ..The future role of capecitabine in the treatment of colorectal cancer and the questions that remain to be answered with regard to its optimal use are considered...
  22. doi request reprint Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
    Colin R Lindsay
    Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK
    Future Oncol 5:421-32. 2009
    ..This article provides a comprehensive and up-to-date synopsis of all pertinent preclinical and clinical studies detailing this promising new therapy...
  23. doi request reprint Adjuvant therapy in colon cancer
    Janet S Graham
    Beatson West of Scotland Cancer Centre, Great Western Road, Glasgow, G12 0YN, Scotland, UK
    Expert Rev Anticancer Ther 12:99-109. 2012
    ..It may be that these patients required treatment with alternative regimens and predictive biomarkers would be particularly helpful...
  24. doi request reprint Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatme
    Janet S Graham
    Cancer Research UK, Department of Medical Oncology, University of Glasgow, Glasgow G61 1BD, UK
    Eur J Cancer 44:2162-8. 2008
    ..Secondary end-points included safety evaluation, tolerability, pharmacokinetic profiling and assessment of response using standard and novel surrogate pharmacodynamic end-points...
  25. ncbi request reprint Oxaliplatin-related side effects: characteristics and management
    Jim Cassidy
    Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Aberdeen, Scotland
    Semin Oncol 29:11-20. 2002
    ..To date, oxaliplatin has proven to be a safe and effective therapy for colorectal cancer and side effects have been easy to manage with appropriate awareness from patients and care providers...
  26. ncbi request reprint Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide
    Gordon J S Rustin
    Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    J Clin Oncol 24:45-51. 2006
    ..Retrospectively, we determined whether the use of this CA-125 definition in a randomized trial would have shown the same magnitude of difference between the treatment arms as was shown when the standard progression definition was used...
  27. ncbi request reprint Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines
    Weiguang Wang
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Aberdeen, UK
    FEBS Lett 531:415-20. 2002
    ..Cerivastatin inhibited nuclear factor kappaB DNA binding activity. The enhancing effect of cerivastatin on 5FU was partially mevalonate pathway independent. Cerivastatin may allow successful 5FU therapy in chemoresistant patients...
  28. ncbi request reprint A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors
    Ramon Salazar
    Cancer Research UK, Department of Medical Oncology, Beatson Laboratories, University of Glasgow, United Kingdom
    Clin Cancer Res 10:4374-82. 2004
    ..This is a dose-finding Phase I study of oral Ro 31-7453, a new class of antimitotic drug with promising preclinical activity in several chemoresistant models...
  29. ncbi request reprint Adjuvant treatment strategies for early colon cancer
    Ashita M Waterston
    Department of Oncology, Cancer Research UK, Beatson Oncology Centre, Glasgow, UK
    Drugs 65:1935-47. 2005
    ....
  30. ncbi request reprint Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases
    Attasit Boonsong
    Department of Medicine and Therapeutics and Pathology, University of Aberdeen Institute of Medical Sciences, Aberdeen, Scotland, UK
    Hum Pathol 33:1114-9. 2002
    ..Topo I expression now needs to be evaluated in patients undergoing topo I-inhibitor therapy, to better define the role of this protein as a predictive marker...
  31. ncbi request reprint Analysis of key cell-cycle checkpoint proteins in colorectal tumours
    Judith A McKay
    Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
    J Pathol 196:386-93. 2002
    ..0266), but it was not an independent predictor of survival. These results suggest that loss of control of cell-cycle checkpoints is a common occurrence in colorectal tumours and may be an important therapeutic target...
  32. ncbi request reprint Liver metastases from breast cancer: management of patients with significant liver dysfunction
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6TN, UK
    Cancer Treat Rev 31:35-48. 2005
    ..In this paper, we review the optimal doses of cytotoxics used in this clinical situation and provide some tips on the management of these patients, based on the limited data currently available in the literature...
  33. ncbi request reprint Emerging drugs in colorectal cancer
    Lucy Scott
    Department of Medical Oncology, Beatson Oncology Center, Western Infirmary, Dumbarton Road, Glasgow, Scotland, UK
    Expert Opin Emerg Drugs 8:193-202. 2003
    ..It is hoped that with the development of these new drugs, the response rates and survival for patients with colorectal cancer will improve from the poor prognosis that many face at present...
  34. ncbi request reprint Chemotherapy in metastatic colorectal cancer
    Claire Kelly
    Department of Medical Oncology, Beatson Oncology Centre, Dumbarton Road, Glasgow G11 6NT, UK
    Surg Oncol 16:65-70. 2007
    ..The review includes discussion of both well established and experimental therapies...
  35. ncbi request reprint Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis
    Sharon Marsh
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
    Oncol Rep 9:231-4. 2002
    ..05 in all cases). Discordance in TS protein levels between primary and secondary tumours demonstrates the danger of predicting outcome after chemotherapy in metastatic colorectal cancer from the primary tumour...
  36. ncbi request reprint Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: a case-control study in the Grampian region of Scotland
    Julian Little
    Epidemiology Group, Department of Public Health, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, UK
    Int J Cancer 119:2155-64. 2006
    ..There was no evidence of interaction between CYP1A1 and smoking, and no evidence of interaction between the GSTM1 or GSTT1 polymorphisms and smoking, meat intake, green leafy vegetable intake, CYP1A1 variants or each other...
  37. ncbi request reprint Striking the right balance in colorectal cancer care--a qualitative study of rural and urban patients
    Norma S C Bain
    Department of General Practice and Primary Care, Foresterhill Health Centre, Aberdeen University Medical School, Westburn Road, Foresterhill, Aberdeen AB25 2AY, Scotland, UK
    Fam Pract 19:369-74. 2002
    ..Colorectal cancer is the second most common cause of cancer-related death in Scotland. For patients, the journey from diagnosis through treatment is complex and there are inequalities in survival rates...
  38. ncbi request reprint Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case-control study in a population with relatively low folate intake
    Linda Sharp
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen AB25 2ZD, UK
    Br J Nutr 99:379-89. 2008
    ..Investigation of particular folate vitamers (for example, tetrahydrofolate, 5,10-methylenetetrahydrofolate) may help clarify carcinogenesis pathways...
  39. ncbi request reprint Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study
    Chris J Twelves
    University of Leeds and Bradford NHS Hospitals Trust, United Kingdom
    Clin Colorectal Cancer 5:101-7. 2005
    ..Capecitabine/oxaliplatin (XelOx) is a safe and active combination for the first-line treatment of metastatic CRC...
  40. ncbi request reprint Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients
    Christopher Poole
    CRC Institute for Cancer Research, University of Birmingham, Birmingham, UK
    Cancer Chemother Pharmacol 49:225-34. 2002
    ..Capecitabine (Xeloda) is an orally administered precursor of 5'-deoxy-5-fluorouridine (5'-DFUR), which is preferentially activated to 5-fluorouracil (5-FU) in tumors...
  41. ncbi request reprint Is the NICE process flawed?
    Jim Cassidy
    Lancet 359:2119-20. 2002
  42. ncbi request reprint Capecitabine plus oxaliplatin in metastatic colorectal cancer
    Jim Cassidy
    J Clin Oncol 25:5043-5; author reply 5045-6. 2007
  43. ncbi request reprint Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer
    Ross Camidge
    Cancer Research UK Centre, Edinburgh, Scotland
    J Clin Oncol 23:4719-25. 2005
    ..This study assessed the influence of capecitabine on the pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin...
  44. ncbi request reprint Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors
    Axel R Hanauske
    Department of Medicine, Asklepios Hospital St Georg, D 20099 Hamburg, Germany
    Clin Cancer Res 13:523-31. 2007
    ..This trial assessed the maximum tolerated dose (MTD), safety, preliminary efficacy, and pharmacokinetics of erlotinib combined with FOLFOX...
  45. doi request reprint Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
    ....
  46. doi request reprint Potential regional differences for the tolerability profiles of fluoropyrimidines
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:2118-23. 2008
    ....
  47. ncbi request reprint Capecitabine as adjuvant treatment for stage III colon cancer
    Chris Twelves
    University of Leeds and Bradford NHS Hospitals Trust, Leeds, United Kingdom
    N Engl J Med 352:2696-704. 2005
    ..The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting...
  48. doi request reprint Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Jim Cassidy
    J Clin Oncol 26:2226-7; author reply 2228. 2008
  49. ncbi request reprint Development and use of radiation detection technology for buried seabed particles
    Jim Cassidy
    Fathoms Ltd, Westover, Langport, Somerset TA10 9RB, UK
    J Radiol Prot 27:A23-37. 2007
    ..Preliminary results of the 2005 ROV work are presented...
  50. ncbi request reprint Vitamin D (and its analogs) in the treatment and prevention of cancer
    Hilary Glen
    Expert Rev Anticancer Ther 6:305-8. 2006